Hyperhomocysteinemia, atherosclerosis and thrombosis

Area of Science:

• Cardiovascular Medicine
• Clinical Chemistry
• Epidemiology

Background:

• Elevated plasma homocysteine, influenced by genetics and environment, is increasingly studied.
• Mild-to-moderate hyperhomocysteinemia is a potential risk factor for thromboembolic diseases.
• Existing evidence on hyperhomocysteinemia and thrombosis risk is conflicting.

Purpose of the Study:

• To evaluate the association between hyperhomocysteinemia and thrombotic risk.
• To determine if hyperhomocysteinemia is a causal risk factor for thrombosis, particularly venous thrombosis.
• To assess the impact of homocysteine-lowering vitamins on preventing thromboembolic events.

Main Methods:

• Review of case-control and cross-sectional studies.
• Analysis of prospective studies examining homocysteine levels and thrombosis.
• Call for prospective cohort studies and randomized, placebo-controlled trials.

Main Results:

• Case-control and cross-sectional studies suggest an association between hyperhomocysteinemia and increased thrombosis risk.
• Prospective studies have not definitively confirmed hyperhomocysteinemia as a high thrombotic risk factor.
• The causal relationship and the efficacy of homocysteine-lowering interventions remain unclear.

Conclusions:

• Further research is essential to clarify the role of hyperhomocysteinemia in thrombosis.
• Prospective cohort studies are needed to establish temporal relationships.
• Randomized trials of homocysteine-lowering vitamins are crucial for definitive conclusions and potential prevention strategies.